Combination drug therapy for Alzheimer's disease: What is evidence-based, and what is not?

Glen Xiong, P. Murali Doraiswamy

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Although FDA-approved Alzheimer's disease (AD) treatment strategies (cholinesterase inhibitors and memantine) offer proven benefits, providers recognize unmet needs beyond what is currently available. Consequently there is a significant use of anecdotal yet unproven combinations for treating AD in practice. Based on the best evidence, combination drug therapy is the standard of care for treating other medical conditions such as malignancies, human immunodeficiency virus (HIV), and hypertension. We review recent combination drug therapy studies in AD. To date, the best evidence-based combination strategy is for moderate-to-severe AD, in which the addition of memantine to stable donepezil therapy was found to benefit cognition, behavior, and function. In milder stages of AD, the benefit of combination drug therapy has not been demonstrated. This review highlights the urgent need to systematically test additional rational drug combinations and the need for future trials to enroll adequate sample sizes and utilize relevant and sensitive outcome measures.

Original languageEnglish (US)
Pages (from-to)22-26
Number of pages5
JournalGeriatrics
Volume60
Issue number6
StatePublished - Jun 2005
Externally publishedYes

Fingerprint

Combination Drug Therapy
Alzheimer Disease
Memantine
Cholinesterase Inhibitors
Drug Combinations
Standard of Care
Sample Size
Cognition
Outcome Assessment (Health Care)
HIV
Hypertension
Therapeutics
Neoplasms

Keywords

  • Alzheimer's disease
  • Cholinesterase inhibitor
  • Memantine combination drug therapy
  • Polypharmacy

ASJC Scopus subject areas

  • Geriatrics and Gerontology

Cite this

Combination drug therapy for Alzheimer's disease : What is evidence-based, and what is not? / Xiong, Glen; Doraiswamy, P. Murali.

In: Geriatrics, Vol. 60, No. 6, 06.2005, p. 22-26.

Research output: Contribution to journalArticle

Xiong, Glen ; Doraiswamy, P. Murali. / Combination drug therapy for Alzheimer's disease : What is evidence-based, and what is not?. In: Geriatrics. 2005 ; Vol. 60, No. 6. pp. 22-26.
@article{6e29685e921244afa5aec1df63f25f57,
title = "Combination drug therapy for Alzheimer's disease: What is evidence-based, and what is not?",
abstract = "Although FDA-approved Alzheimer's disease (AD) treatment strategies (cholinesterase inhibitors and memantine) offer proven benefits, providers recognize unmet needs beyond what is currently available. Consequently there is a significant use of anecdotal yet unproven combinations for treating AD in practice. Based on the best evidence, combination drug therapy is the standard of care for treating other medical conditions such as malignancies, human immunodeficiency virus (HIV), and hypertension. We review recent combination drug therapy studies in AD. To date, the best evidence-based combination strategy is for moderate-to-severe AD, in which the addition of memantine to stable donepezil therapy was found to benefit cognition, behavior, and function. In milder stages of AD, the benefit of combination drug therapy has not been demonstrated. This review highlights the urgent need to systematically test additional rational drug combinations and the need for future trials to enroll adequate sample sizes and utilize relevant and sensitive outcome measures.",
keywords = "Alzheimer's disease, Cholinesterase inhibitor, Memantine combination drug therapy, Polypharmacy",
author = "Glen Xiong and Doraiswamy, {P. Murali}",
year = "2005",
month = "6",
language = "English (US)",
volume = "60",
pages = "22--26",
journal = "Geriatrics",
issn = "0016-867X",
publisher = "Advanstar Communications",
number = "6",

}

TY - JOUR

T1 - Combination drug therapy for Alzheimer's disease

T2 - What is evidence-based, and what is not?

AU - Xiong, Glen

AU - Doraiswamy, P. Murali

PY - 2005/6

Y1 - 2005/6

N2 - Although FDA-approved Alzheimer's disease (AD) treatment strategies (cholinesterase inhibitors and memantine) offer proven benefits, providers recognize unmet needs beyond what is currently available. Consequently there is a significant use of anecdotal yet unproven combinations for treating AD in practice. Based on the best evidence, combination drug therapy is the standard of care for treating other medical conditions such as malignancies, human immunodeficiency virus (HIV), and hypertension. We review recent combination drug therapy studies in AD. To date, the best evidence-based combination strategy is for moderate-to-severe AD, in which the addition of memantine to stable donepezil therapy was found to benefit cognition, behavior, and function. In milder stages of AD, the benefit of combination drug therapy has not been demonstrated. This review highlights the urgent need to systematically test additional rational drug combinations and the need for future trials to enroll adequate sample sizes and utilize relevant and sensitive outcome measures.

AB - Although FDA-approved Alzheimer's disease (AD) treatment strategies (cholinesterase inhibitors and memantine) offer proven benefits, providers recognize unmet needs beyond what is currently available. Consequently there is a significant use of anecdotal yet unproven combinations for treating AD in practice. Based on the best evidence, combination drug therapy is the standard of care for treating other medical conditions such as malignancies, human immunodeficiency virus (HIV), and hypertension. We review recent combination drug therapy studies in AD. To date, the best evidence-based combination strategy is for moderate-to-severe AD, in which the addition of memantine to stable donepezil therapy was found to benefit cognition, behavior, and function. In milder stages of AD, the benefit of combination drug therapy has not been demonstrated. This review highlights the urgent need to systematically test additional rational drug combinations and the need for future trials to enroll adequate sample sizes and utilize relevant and sensitive outcome measures.

KW - Alzheimer's disease

KW - Cholinesterase inhibitor

KW - Memantine combination drug therapy

KW - Polypharmacy

UR - http://www.scopus.com/inward/record.url?scp=20544449738&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20544449738&partnerID=8YFLogxK

M3 - Article

C2 - 15948662

AN - SCOPUS:20544449738

VL - 60

SP - 22

EP - 26

JO - Geriatrics

JF - Geriatrics

SN - 0016-867X

IS - 6

ER -